Amerikanische Gesellschaft für Hirudotherapie

Successful pediatric heart transplantation with bivalirudin use in a cyanotic single ventricle patient with an intracorporeal continuous flow ventricular assist device and heparin-induced thrombocytopenia

Case report published in Indian Journal of Thoracic and Cardiovascular Surgery (2025)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Case reportKlinische StudienArzneimittelentwicklungSainathan S, Mulinari L · Indian Journal of Thoracic and Cardiovascular Surgery, 2025

Abstract

We describe a case of profound coagulopathy during orthotopic heart transplantation in a cyanotic single ventricle pediatric patient with an intracorporeal continuous flow ventricular assist device performed on bivalirudin for heparin-induced thrombocytopenia. This was successfully managed with central veno-arterial extracorporeal membrane oxygenation and hemofiltration as an adjunct to treat bivalirudin-induced coagulopathy due to lack of a reversal agent for bivalirudin.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeCase ReportsJournal Article

Zusammenfassung

Successful orthotopic heart transplant in a cyanotic single ventricle pediatric patient on continuous-flow VAD with HIT, with bivalirudin anticoagulation managed using V-A ECMO and hemofiltration as adjuncts due to lack of bivalirudin reversal agent.

Warum dies für die Hirudotherapie relevant ist

This case report describes a cyanotic single-ventricle pediatric patient with an intracorporeal continuous-flow ventricular assist device and heparin-induced thrombocytopenia who underwent orthotopic heart transplantation anticoagulated with bivalirudin. Profound coagulopathy developed and was managed with central veno-arterial extracorporeal membrane oxygenation and hemofiltration, partly because bivalirudin lacks a reversal agent. The abstract does not mention hirudin, leeches, leech therapy, or the leech secretome, so no direct connection to hirudotherapy can be made from this source. Relevance to ASH's domain, if any, is not established by the abstract. The evidence is limited to a single case report with minimal detail on outcomes beyond acute management.

Zitation

Successful pediatric heart transplantation with bivalirudin use in a cyanotic single ventricle patient with an intracorporeal continuous flow ventricular assist device and heparin-induced thrombocytopenia.

Sainathan S, Mulinari L · Indian Journal of Thoracic and Cardiovascular Surgery, 2025

Verwandter klinischer Kontext

Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.